Literature DB >> 16265684

The predictive value of rheumatoid factor isotypes, anti-cyclic citrullinated peptide antibodies, and antineutrophil cytoplasmic antibodies for mortality in patients with rheumatoid arthritis.

Susanna Sihvonen1, Markku Korpela, Anu Mustila, Jukka Mustonen.   

Abstract

OBJECTIVE: To evaluate the significance of rheumatoid factor (RF) and its isotypes (IgA RF, IgG RF, and IgM RF), anti-cyclic citrullinated peptide antibodies (anti-CCP), and antineutrophil cytoplasmic antibodies (ANCA) in predicting mortality in patients with rheumatoid arthritis (RA).
METHODS: The study population comprised 604 patients with RA participating in a cross-sectional study in 1987. Presence of RF (n = 604), RF isotypes (n = 206), anti-CCP (n = 184), and ANCA (n = 200) were determined in these patients from available baseline sera. Vital status was assessed in 1999 and multivariate Cox regression analysis used to compare mortality in RA patients with or without different antibodies.
RESULTS: Of the 604 patients with RA, 55% were positive for RF, 66% for anti-CCP, and 14.5% for perinuclear ANCA. Twelve patients (19%) with RF were anti-CCP-negative and 34 (40%) without RF were anti-CCP-positive. Of the total 604 patients, 160 had died by 1999. Positive RF and high IgA and IgM RF levels predicted increased mortality, while positive anti-CCP or ANCA did not. However, high anti-CCP levels were related to an increased mortality risk.
CONCLUSION: Patients with RA with positive RF, especially IgA and IgM isotypes, carry a risk of dying earlier than patients without these serological findings.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16265684

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  15 in total

1.  Second generation automated anti-CCP test better predicts the clinical diagnosis of rheumatoid arthritis.

Authors:  Mohamed Elrefaei; Kristie Boose; Martha McGee; Teresa K Tarrant; Feng-Chang Lin; Jason P Fine; John L Schmitz
Journal:  J Clin Immunol       Date:  2011-11-10       Impact factor: 8.317

Review 2.  Antibodies to citrullinated protein antigens (ACPAs): clinical and pathophysiologic significance.

Authors:  M Kristen Demoruelle; Kevin Deane
Journal:  Curr Rheumatol Rep       Date:  2011-10       Impact factor: 4.592

3.  The continuous measurement of anti-CCP-antibodies does not help to evaluate the disease activity in anti-CCP-antibody-positive patients with rheumatoid arthritis.

Authors:  Thoren Landmann; Gabriele Kehl; Raoul Bergner
Journal:  Clin Rheumatol       Date:  2010-09-14       Impact factor: 2.980

4.  Rheumatoid factor and antibodies to cyclic citrullinated peptides are associated with severe extra-articular manifestations in rheumatoid arthritis.

Authors:  C Turesson; L T H Jacobsson; G Sturfelt; E L Matteson; L Mathsson; J Rönnelid
Journal:  Ann Rheum Dis       Date:  2006-08-10       Impact factor: 19.103

5.  Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis.

Authors:  Lennart T H Jacobsson; Carl Turesson; Jan-Ake Nilsson; Ingemar F Petersson; Elisabet Lindqvist; Tore Saxne; Pierre Geborek
Journal:  Ann Rheum Dis       Date:  2006-12-11       Impact factor: 19.103

6.  Determinants of mortality among postmenopausal women in the women's health initiative who report rheumatoid arthritis.

Authors:  Lewis H Kuller; Rachel H Mackey; Brian T Walitt; Kevin D Deane; V Michael Holers; William H Robinson; Jeremy Sokolove; Yuefang Chang; Simin Liu; Christine G Parks; Nicole C Wright; Larry W Moreland
Journal:  Arthritis Rheumatol       Date:  2014-03       Impact factor: 10.995

7.  Cigarette smoking, disease severity and autoantibody expression in African Americans with recent-onset rheumatoid arthritis.

Authors:  T R Mikuls; L B Hughes; A O Westfall; V M Holers; L Parrish; D van der Heijde; M van Everdingen; G S Alarcón; D L Conn; B Jonas; L F Callahan; E A Smith; G Gilkeson; G Howard; L W Moreland; S L Bridges
Journal:  Ann Rheum Dis       Date:  2008-01-15       Impact factor: 19.103

8.  Benefit of early treatment in inflammatory polyarthritis patients with anti-cyclic citrullinated peptide antibodies versus those without antibodies.

Authors:  Tracey M Farragher; Mark Lunt; Darren Plant; Diane K Bunn; Anne Barton; Deborah P M Symmons
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-05       Impact factor: 4.794

9.  A systematic review of serum biomarkers anti-cyclic citrullinated Peptide and rheumatoid factor as tests for rheumatoid arthritis.

Authors:  Peter Taylor; Juliane Gartemann; Jeanie Hsieh; James Creeden
Journal:  Autoimmune Dis       Date:  2011-09-11

10.  Association of the HLA-DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis.

Authors:  Tracey M Farragher; Nicola J Goodson; Haris Naseem; Alan J Silman; Wendy Thomson; Deborah Symmons; Anne Barton
Journal:  Arthritis Rheum       Date:  2008-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.